Ignite Creation Date:
2025-12-25 @ 1:06 AM
Ignite Modification Date:
2026-02-08 @ 11:11 AM
Study NCT ID:
NCT01794793
Status:
COMPLETED
Last Update Posted:
2024-10-01
First Post:
2013-02-15
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
Sponsor:
RECORDATI GROUP
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Cushing's Disease | View |
| None | Acromegaly | View |
| None | Neuroendocrine Tumors | View |
| None | Pituitary Tumors | View |
| None | Ectopic ACTH Secreting (EAS) Tumors | View |
| None | Dumping Syndrome | View |
| None | Prostate Cancer | View |
| None | Melanoma Negative for bRAF | View |
| None | Melanoma Negative for nRAS | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | SOM230, | View |
| None | roll-over study | View |
| None | pasireotide LAR | View |
| None | Cushing's disease | View |
| None | Acromegaly | View |
| None | neuroendocrine tumorsNETs | View |
| None | pituitary tumors | View |
| None | Ectopic ACTH secreting | View |
| None | EAS | View |
| None | Dumping Syndrome | View |
| None | metastatic prostate cancer, metastatic melanoma | View |
| None | bRAF | View |
| None | nRAS | View |